DeepMed Research

Anecortave

Generic Name: Anecortave

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₄

CAS Number: 10184-70-0

Unique Ingredient Identifier: R5Y8O51589

Background: Anecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension).

Clinical Trials

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Terminated

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Anecortave Acetate Sterile Suspension, 96 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 60 mg/ML
Drug: Anecortave Acetate Sterile Suspension, 6 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 3.75 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2008-11-11

Last Posted Date: 2012-11-30

Lead Sponsor: Alcon Research

Target Recruit Count: 197

Registration Number: NCT00788541

Locations: 🇺🇸
Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Open-angle Glaucoma
Oular Hypertension

Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 75 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2008-06-05

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 201

Registration Number: NCT00691717

Locations: 🇺🇸
Charleston, Charleston, South Carolina, United States

Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

Phase 1

Completed

Conditions: Chronic Central Serous Chorioretinopathy

Interventions: Drug: Anecortave Acetate Sterile suspension 15 mg
Drug: Anecortave Acetate

First Posted Date: 2007-06-21

Last Posted Date: 2012-10-25

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 5

Registration Number: NCT00489840

Locations: 🇺🇸
Manhattan Eye, ear & Throat Institute, New York, New York, United States
🇺🇸
Vitreous-Retina-Macula Consultants of New York,PC, New York, New York, United States

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

Phase 2

Completed

Conditions: Open-angle Glaucoma

Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2007-03-23

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 89

Registration Number: NCT00451152

Locations: 🇺🇸
Texas, San Antonio, Texas, United States

A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

Phase 2

Completed

Conditions: AMD

Interventions: Drug: Anecortave Acetate 15 mg
Drug: Anecortave acetate 30 mg
Drug: Anecortave Acetate 3 mg
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-07-04

Last Posted Date: 2012-03-06

Lead Sponsor: Alcon Research

Target Recruit Count: 128

Registration Number: NCT00346957

Anecortave Acetate Risk-Reduction Trial (AART)

Phase 3

Terminated

Conditions: AMD

Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 60 mg/ML
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-06-02

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 24

Registration Number: NCT00333216

Locations: 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States

Anecortave Acetate Risk Reduction Trial (AART)

Phase 3

Terminated

Conditions: AMD

Interventions: Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-06-02

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 36

Registration Number: NCT00332657

Locations: 🇮🇳
India, Bangalore, India

Anecortave Acetate in Patients With Open-angle Glaucoma

Phase 2

Completed

Conditions: Open-angle Glaucoma

Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 6 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-05-03

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 86

Registration Number: NCT00320203

Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

Phase 2

Completed

Conditions: Eye Diseases

Interventions: Drug: Anecortave Acetate Sterile Suspension, 6 mg/mL
Drug: Anecortave Acetate Suspension Depot, 30 mg/mL
Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-04-19

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 70

Registration Number: NCT00315640

Locations: 🇵🇷
Bayamon, Bayamon, Puerto Rico
🇭🇺
Budapest, Budapest, Hungary
🇳🇱
Amsterdam, Amsterdam, Netherlands

and more 8 locations

Anecortave Acetate Risk-Reduction Trial (AART)

Phase 3

Terminated

Conditions: Dry AMD

Interventions: Drug: Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg
Other: Anecortave Acetate Vehicle

First Posted Date: 2006-03-28

Last Posted Date: 2012-11-28

Lead Sponsor: Alcon Research

Target Recruit Count: 2596

Registration Number: NCT00307398

Locations: 🇺🇸
Study Centers in the United States and Globally, Fort Worth, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy